Scinai Immunotherapeutics (SCNI) FCF Margin (2024 - 2026)
Scinai Immunotherapeutics' (SCNI) quarterly FCF Margin came in at 511.3% in Q2 2026, up 30741.0% year-over-year from N/an in Q2 2025, and down 72.08% quarter-over-quarter from 297.14% in Q1 2026.
Powered by 
Analysis
Scinai Immunotherapeutics (SCNI) FCF Margin (2024 - 2026) Analysis & Trends
Scinai Immunotherapeutics has disclosed FCF Margin across 3 years of filings, most recently posting 511.3% for Q2 2026.
- In Q2 2026, FCF Margin rose 30741.0% year-over-year to 511.3%; the TTM figure through Jun 2026 stood at 369.8% (up 12479.0% YoY), while the FY2025 annual figure was 251.44%, up 70950.0% from the prior year.
- FCF Margin came in at 511.3% for Q2 2026 at Scinai Immunotherapeutics, down from 297.14% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 176.11% in Q1 2025 to a low of 1210.71% in Q3 2024.
- Average FCF Margin over 3 years is 589.39%, with a median of 516.82% recorded in 2024.
- The largest YoY upside for FCF Margin was 30741 bps in 2026 against a maximum downside of 12103 bps in 2026.
- Over 3 years, FCF Margin stood at 522.33% in 2024, then sank by 57 bps to 818.72% in 2025, then soared by 38 bps to 511.3% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 511.3% in Q2 2026, 297.14% in Q1 2026, and 818.72% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -18,629.40% |
| 10 | Scinai Immunotherapeutics | 1.52 Bn | 1.52 Bn | -1.25 Mn | -511.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -511.30% |
| Mar 31, 2026 | -297.14% |
| Jun 30, 2025 | -818.72% |
| Mar 31, 2025 | -176.11% |
| Dec 31, 2024 | -522.33% |
| Sep 30, 2024 | -1,210.71% |